Announced that the first open heart failure patients has been dosed in the Phase Ib http://viagrapriser.com/naturlig-viagra.html.

Nile Therapeutics Announces Initiation of the Heart Failure Patient in Phase Ib Study of CD-NPNile Therapeutics, , announced that the first open heart failure patients has been dosed in the Phase Ib, multi – center,-label, ascending dose clinical trial of the company’s lead compound, a novel chimeric natriuretic peptide in development for the treatment of acute decompensated heart failure. ‘We are very pleased that dosing in this important in this important dose – escalation study of CD-NP in patients with heart failure,’said Peter Strumph, Chief Executive Officer of the Nile. ‘CD-NP has unmet medical need fill a large unmet medical need in the treatment of heart failure http://viagrapriser.com/naturlig-viagra.html . This study gives us the first opportunity to evaluate the activity of the drug in patients with heart failure and our understanding our understanding of the molecule mechanism of action. ‘.

About CD-NPcreate CD – NP is a rationally designed synthetic peptide selected from naturally occurring components natriuretic peptides, a novel, NPR-B agonist which has a favorable pharmacological profile with potent renal enhancement and cardiac links unloading properties, but minimal hypotensive effect. Data from recently completed Phase Nils Ia study in 22 healthy volunteers were consistent with several pre-clinical results, including CD-NP increased plasma cGMP, a secondary messenger of the target receptor, preserved renal function was associated, increased natriuresis and diuresis without effect on mean arterial pressure. In the U.S..

Writer Contact: Helen H. Hobbs University of Texas Southwestern Medical Center,Jonathan C. Cohen, University of Texas Southwestern Medical Center,View PDF of this article at:IMMUNOLOGY: Do not scratch may itch: locking of protein IL-21R helps prevent a shape by eczema.